Research articlePublished 22 Jan 2018
Effects of Plasmalogen on Patients with Mild Cognitive Impairment: A Randomized, Placebo-Controlled Trial in Japan
1Institute of Rheological Functions of Food, Hisayama-machi, Kasuya-gun, Fukuoka, Japan; 2Gotanda Rehabilitation Hospital, Shinagawa-ku, Tokyo, Japan; 3Memory Clinic Ochanomizu, Yushima, Bunkyo-ku, Tokyo, Japan; 4BOOCS Holistic Clinic Tokyo, Chuo-ku, Tokyo, Japan; 5Department of Neurology, School of Medicine, Fukuoka University, Johnan-ku, Fukuoka, Japan; 6BOOCS Clinic Fukuoka, Hakata-ku, Fukuoka, Japan
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Objective: It has been shown that plasmalogens (Pls) in the brain tissue and blood decrease among Alzheimer’s disease (AD) patients. We first confirmed the effects of Pls on animal AD models, and subsequently reported that the ingestion of 1 mg Pls was effective for AD patients in a randomized, placebo-controlled trial with mild cognitive impairment (MCI) or mild AD patients. The present study examined the efficacy of orally administered Pls on patients with MCI enrolled in the previous trial in terms of individual domains of the Mini Mental State Examination-Japanese (MMSE-J). Methods: The present analysis used 178 patients with MCI out of the 276 patients with either MCI or AD in the previously reported trial, and assessed the 24 week change in the domain-specific scores of the MMSE-J. Originally, the randomized, placebo-controlled trial was performed for 276 patients at age of 60-85 years who had the MMSE-J score of 20-27 points and the Geriatric Depression Scale-Short Version-Japanese Version (GDS-S-J) score of 5 points or less. The patients were randomly allocated to either a treatment with 1 mg of scallop-derived Pls daily or a placebo treatment. The primary outcome was a 24 week change in the MMSE-J. The registered number of the trial is UMIN000014945. Results: The MMSE-J total score improved statistically significantly in the Pls treatment but not in the placebo treatment, resulting in no significant between-treatment difference. With respect to one of the MMSE-J domains, orientation to place, the Pls treatment showed a significant improvement and the placebo treatment showed no such improvement; the between-treatment difference was statistically significant (p=0.003). The domain for orientation to time worsened significantly at endpoint in the placebo treatment, while the Pls treatment showed no worsening. However, the between-treatment difference failed to reach the statistical significance. No significant change was found in either treatment regarding the other MMSE-J domains. Conclusion: These findings suggest that oral administration of 1 mg Pls enhances cognitive function of MCI patients, especially orientation to place.
Keywords
Subjects
Neuroscience & NeurologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Alzheimers Disease & Parkinsonism
- SubjectNeuroscience & Neurology
- BylineArticles whose byline prints “Takehiko Fujino”
- BylineArticles whose byline prints “Tatsuo Yamada”
- BylineArticles whose byline prints “Takashi Asada”
- BylineArticles whose byline prints “Midori Ichimaru”
- BylineArticles whose byline prints “Yoshio Tsuboi”
- BylineArticles whose byline prints “Chikako Wakana”
- BylineArticles whose byline prints “Shiro Mawatari”